论文部分内容阅读
Thompson等报告,在肾移植患者应用甲氧苄氨嘧啶(TMP)或复方新诺明(TMP+SMZ)与环孢霉素(Cyclosporin)联合用药时,血清肌酐显著升高。而在健康人和未作肾移植的患者给予上述药物时,血清肌酐并不升高或至多升高10-15%。但是,在肾移植患者,TMP与硫唑嘌呤联合用药时,血清肌酐水平不变。TMP合用环孢霉素时所引起的肾脏损害认为是两种对肾脏有潜在毒性的药物相加作用的结果。作者在4例肾移植患者中证实TMP与环孢霉素合用时血清肌酐升高。在应用TMP的2-3天后,肾功开始恶化,在停药后的一周内恢复到治疗前水平。此外,与Thompson等报告不同,作者在肾
Thompson et al. Reported that serum creatinine was significantly elevated in patients receiving renal transplantation with trimethoprim (TMP) or cotrimoxazole (TMP + SMZ) in combination with cyclosporin. Serum creatinine did not increase or increased at most by 10-15% in healthy and non-renal transplant patients. However, serum creatinine levels did not change in renal transplant recipients when TMP was administered in combination with azathioprine. Kidney damage caused by TMP in combination with cyclosporine is thought to be the result of two additive drugs that are potentially toxic to the kidneys. The authors confirmed that serum creatinine increased when TMP was administered with cyclosporine in 4 renal transplant recipients. Renal function began to worsen after 2-3 days of application of TMP and returned to pretreatment levels within a week after withdrawal. In addition, unlike reports by Thompson et al., The authors are in the kidney